Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
about
The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapiesGuidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelinesThe emerging role of ofatumumab in the treatment of chronic lymphocytic leukemiaEvaluation of an Ontology-anchored Natural Language-based Approach for Asserting Multi-scale Biomolecular Networks for Systems MedicineChronic lymphocytic leukemia: a clinical review including Korean cohortsChronic Lymphocytic Leukemia in the Elderly, Which Investigations Are Necessary: A Map for the Practicing OncologistIdentifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without ImmunotherapyPhase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemiaDoes total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia?Alemtuzumab for B-cell chronic lymphocytic leukemia.The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomesAggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks.Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China.The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia.Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.Detection, analysis and clinical validation of chromosomal aberrations by multiplex ligation-dependent probe amplification in chronic leukemia.Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we goAcquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants.Ontology-anchored Approaches to Conceptual Knowledge Discovery in a Multi-dimensional Research Data Repository.Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia.A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphomaModern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroupsMicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease.How I treat CLL up front.Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocationMulti-dimensional discovery of biomarker and phenotype complexesDipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemiaDetection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.Allogeneic hematopoietic cell transplantation in the treatment of chronic lymphocytic leukemia: why and when?Conceptual dissonance: evaluating the efficacy of natural language processing techniques for validating translational knowledge constructs.Prognostic information and biological insights in chronic lymphocytic leukemia by high-resolution immunophenotypic analysis of ZAP70.A pathobiological role of the insulin receptor in chronic lymphocytic leukemia.Cladribine: not just another purine analogue?Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia.Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997.p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden.
P2860
Q24605471-9DDCDF1C-51DC-4AB5-B136-98F4478531E4Q24616084-A2BDD8ED-42EF-46F4-8EC3-3AADCFA82005Q24617708-6E4002CB-3107-48BB-94DD-EB284F83B0E2Q24619083-D6C77860-613C-4C54-A73D-AA086751AE86Q26752467-A2D8F066-7DD0-4FD1-86A5-5625723A2FBBQ26775986-2314EB7C-B428-425B-93B3-2784DDE383DDQ28077136-CBDD1D30-0577-448A-B9A1-AFF8DC9286BFQ28261949-CB391A9B-77D2-4D89-B3F4-B256B8FEB91AQ30407633-6AE733EE-9946-431A-B0F0-579D9BA0015DQ33380135-0B78DA6C-8F9F-4130-9DD4-BDF7CB6F080DQ33409459-EA57FA45-52D3-4167-889F-73E1DE7572CAQ33438825-51D71D81-7258-4D2F-BA49-E700FF1730C6Q33558148-B0106D6D-8DB0-42F5-B6A3-19E541A15FF4Q33638819-2FD65875-2A4C-4194-AE7C-014F3E212707Q33649977-2A05B474-D332-41DC-81BF-4E3B0B215559Q33688473-B2B8DA43-6581-4718-8749-5CD7973F690FQ33708995-6C20F172-D861-4E9C-83B4-A7DAA3AB87B2Q33737795-1F117455-CD67-46CB-8CF3-6A17EFB822FDQ33744997-7924FEB2-469D-4F43-9E63-7E63B369BE8FQ33818637-AD2E1C17-A9DD-4B3F-97B6-A94CC2A8169CQ33828204-1F4E7335-34A4-4D39-A4E0-05228B48396FQ33886052-FA1914AE-19E3-40C1-80C5-AFA5E3F60AEEQ33905245-B78CF957-2C79-4370-B7E1-A4A53B218261Q33913537-1132F0D2-325A-4482-8D47-7754F7A61575Q33942272-83F5B49B-866F-48A8-B967-746764D94984Q33987045-2BD78D8C-D6CD-49D2-A991-546F8E3A2C47Q34137158-83755FB7-A60F-485E-86CD-9F5FC3E6A69BQ34166551-5557A8AD-99CC-4D29-BB1B-464BA897F707Q34259504-D47786B8-B2B5-4D90-8C8A-3D451FAB7C7CQ34349298-53A4917E-1180-4C7C-A2DC-E42D1A37AB7AQ34461989-486AEF6E-C473-49E9-8127-2A2E07F6A58EQ34549285-9B94FD6F-E01E-4FF5-A247-6D7ED3F2736FQ34585030-A0274255-B84F-4068-A1FB-3B12C8412629Q34781837-8DB43D44-5CE2-40AF-95B7-2A793EB7FD28Q34917625-4A6682D6-FC8C-45C1-B93D-A79800C4AE7CQ34992373-97573C63-78F3-4F46-BD6B-4F6D52F20BB2Q35025733-BC46DE72-85FD-4D31-B047-BD1CD17A006EQ35266160-C63EF865-B871-4E21-B8C9-095C30985C33Q35597328-6656D067-A19F-4234-B08F-6540A2DBD00AQ35676442-33BA49C2-A6ED-4A69-8121-4A0EC5B73BB3
P2860
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Comprehensive assessment of ge ...... ergroup Phase III Trial E2997.
@en
Comprehensive assessment of ge ...... ergroup Phase III Trial E2997.
@nl
type
label
Comprehensive assessment of ge ...... ergroup Phase III Trial E2997.
@en
Comprehensive assessment of ge ...... ergroup Phase III Trial E2997.
@nl
prefLabel
Comprehensive assessment of ge ...... ergroup Phase III Trial E2997.
@en
Comprehensive assessment of ge ...... ergroup Phase III Trial E2997.
@nl
P2093
P50
P921
P356
P1476
Comprehensive assessment of ge ...... ergroup Phase III Trial E2997.
@en
P2093
David M Lucas
Diane F Jelinek
Donna S Neuberg
Gordon W Dewald
John C Reed
John G Gribben
Michael R Grever
Shinichi Kitada
P304
P356
10.1200/JCO.2006.08.3089
P407
P577
2007-02-05T00:00:00Z